



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C47
Serial No: 10/015,671 Group Art Unit: 1647
Filed: December 11, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.



Napoleone Ferrara, Ph.D.

10/4/04

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.


Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C47
Serial No: 10/015,671 Group Art Unit: 1647
Filed: December 11, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:


1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.


5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date





Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.

Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C47
Serial No: 10/015,671 Group Art Unit: 1647
Filed: December 11, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.

Date



Paul J. Godowski, Ph.D.

10/05/01

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.


Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C47
Serial No: 10/015,671 Group Art Unit: 1647
Filed: December 11, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.


Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date


Austin Gurney, Ph.D.

Date


10/5/04

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C47
Serial No: 10/015,671 Group Art Unit: 1647
Filed: December 11, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "^insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date



James Pan, Ph.D.



Date

Austin Gurney, Ph.D.


Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C47
Serial No: 10/015,671 Group Art Unit: 1647
Filed: December 11, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.


Date

James Pan, Ph.D.


Date

Austin Gurney, Ph.D.

Date




Colin K. Watanabe



Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C47
Serial No: 10/015,671 Group Art Unit: 1647
Filed: December 11, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.

Date

Colin K. Watanabe

Date



William I. Wood, Ph.D.



Date


```

mnII      aluI
alwNI[dcM-]
alw26I/bsmAI      bsaxI      hpy188I      mspAII/nspBII      bsmAI
101 CAGCCTCTGC CCAAGAAAG AAGGAGATGG TGTATCTGA AAAGTTAGT CAGCTGATGG AATGGACTAA CAAAAGACCT GTAATAAGAA TGAATGGAGA
    GTCGAGAGCG GGTTCCTTTC TTCCTCTACC ACAATAGACT TTTCCAATCA GTCGACTACC TTACCTGATT GTTTCTGGA CATTATCTT ACTTACCTCT
27  A S A Q R X K E M V L S E K V S Q L M E W T N K R P V I R M N G D

      tspRI      bst4CI/hpyCH4III      cac8I
      btsI      ahdI/eam1105I      cac8I
      nlaIII      hpyCH4V tspRI      hpyCH4V al
      tsp509I
hpy99I
201 CAAGTCCGT CGCCTTGTA AAGCCCCACC GAGAAATTAC TCCGTTATCG TCATGTTTAC TGCTCTCCAA CTGCATAGAC AGTGTGTCGT TTGCAAGCAA
    GTTCAAGGA GCGGAACACT TTCGGGGTGG CTCTTTAATG AGGCAATAGC AGTACAAGTG ACGAGAGGTT GACGTATCTG TCACACAGCA AACGTTGTT
60 K F R R L V K A P P R N Y S V I V M F T A L Q L H R Q C V V C K Q

```

```

scrFI[dcn-]
pspGI
mvaI
ecoRII[dcn-]
dsaV[dcn-]
bstNI
bssKI[dcn-]
apyI[dcn+]
sau3AI
mboI/hdeII[dam-]
dpsII[dam-]
dpsI[dam+]
alwI[dam-]
bstYI/xhoII
alwNI[dcn-]
alw26I/bsmAI
tsp509I[M.ecoRI-]
ecoRI pflMI[dcn-]
apoI bslI[dcn-]
mboII hpy188III
301 GCTGATGAAG AATTCCAGAT CCTGGCAAC CCTCCAGTGC ATTCACCAAC AGGATATTTT TTCCATGGT GGATTTTGGT GAAGGCTCTG
CGACTACTTC TTAAGGTCTA GGACCGTTTG AGGACCGCTA TGAGGTCCAG TAAGTGGTGG TCCTATAAAA AAGGTACCA CCTAAAACTA CTTCCGAGAC
93 A D E E F Q I L A N S W R Y S S A F T N R I F F A M V D F D E G S D

```


tsp509I[M.ecoRI-]
 ecoRI hpyCH4V
 apoI econI
 sfanI hpy188I nlaIII aluI bslI hphI ndeI maeIII acII
 401 ATGATATTCA GATGCTAAAC ATGAATTGAG CTCCAACCTT CATCAACTTT CTGCAAAAG GGAACCCAA ACGGGTGAT ACATATGAGT TACAGGTGCG
 TACATAAAGT CTACGATTG TACTTAAGTC GAGGTGAAA GTACTTGAAA GGACGTTTTC CCTTTGGGTT TGCCCCACTA TGTATACTCA ATGTCCACGC
 127 V F Q M L N M N S A P T F I N F P A K G K P K R G D T Y E L Q V R

ddel[M.aluI-]
 bspCNI mspI sau3AI
 cellI/espI hpaII mboI/ndeII[dam-]
 b1pI/bp1102I scrFI[M.hpaII-]
 aluI nciI dpnII[dam-]
 pvuII dsav dpnI[dam+]
 mspAII/nspBII bssKI alwI[dam-] sspI
 501 GGGTTTTC GCTGAGCAGA TTGCCCGGTG GATCGCCGAC AGAAGTATG TCAATATTAG AGTGATTAGA CCCCCAAATT ATGCTGGTCC CCTATGTTG
 CCCAAAAGT CGACTCGTCT AACGGGCCAC CTAGCGGTG TCTTGACTAC AGTTATAATC TCACTAATCT GGGGGTTTAA TACGACCAGG GGAATACAAC
 160 G F S A E Q I A R W I A D R T D V N I R V I R P P N Y A G P L M L

taqi aluI
 sfiI tseI
 bstBI fnu4HI/bsoFI
 bsiCI foki bstF5I bbvI
 baeI mboII mboII apoI mseI bsrI mwoI hpyCH4V
 601 GGATTGCTTT TGGCTGTAT TGGTGGACTT GTGTATCTTC GAAGAACTAA TATGGAATTT CTCTTTAATA AAACGTGGATG GGCTTTTGCA GCCTTTGTGTT
 CCTAACGAAA ACCGACAATA ACCACCTGAA CACATAGAAG CTTCCTTCATT ATACCTTAAA GAGAAATTAT TTTGACCTAC CCGAAAACGT CGAAACACAA
 193 G L L L A V I G G L V Y L R R S N M E F L F N K T G W A F A A L C F

bsmFI
 sau96I
 nlaIV
 avall
 tru9I ppuMI
 aluI hpy188I mseI eco0109I/draII
 1001 ATGGCTACCC ATACAGCTTT CTGATGAGTT AAAAAGGTCC CAGAGATATA TAGACACTGG AGTACTGGAA ATTGAATAAC GAAATCGTG TGTGTTTGAA
 TACCGATGGG TATGTCGAAA GACTACTCAA TTTTCCAGG GTCTCTATAT ATCTGTGACC TCATGACCTT TAACTTTTGG CTTTTAGCAC ACACAAACTT
 327 G Y P Y S F L M S O

bsmI
 mboII hpyCH4V
 mnlI
 1101 AAGAAGAAG CAACCTGTAT ATTTGTATT ACCCTTTT TCAAGTGAT TTAATAGTT AATCATTAA CCAAAGAAGA TGTGTAGTG CTTAACAAGC
 TTCTTCTTAC GTTGAACATA TAAACATAA TGGAGAAAAA AAGTTCACATA AATTATCAA TTAGTAAATT GGTTCCTTCT ACACATCAGG GAATTGTTTCG

mnlI
 ddeI
 bspCNI
 hpy188I
 1201 AATCCTCTGT CAAATCTGA GGTATTGAA AATAATTATC CTCTTAACCT TCTCTTCCCA GTGAACTTTA TGAACATTTT AATTAGTAC AATTAAGTAT
 TTAGGAGACA GTTTTAGACT CCATAAACTT TTATTAATAG GAGAATTGGA AGAGAAGGCT CACTTGAAT ACCTGTAAA TTAATCATG TTAATTCATA

psiI tsp509I
 1301 ATTATAAAAA TTGTAAAACT ACTACTTTGT TTTAGTAGA ACAAGCTCA AAACACTCTT AGTTAACTTG GTCATCTGAT TTTATATTGC CTTATCCAAA
 TAAATATTTT AACATTTTGA TGATGAAACA AAATCAATCT TGTTCGAGT TTTGATGAAA TCAATTGAAC CAGTAGACTA AAATATAACG GAATAGGTTT

scrFI[dcM-]

pspGI

mvaI

ecoRII[dcM-]

dsaV[dcM-]

bstNI

bssKI[dcM-]

apyI[dcM+]

sexAI

hpy188III

ndeI

maeIII

apoI

ddeI[M.aluI-]

fokI

bstF5I

1401 GATGGGGAAA GTAAGTCCTG ACCAGGTGTT CCCACATATG CCTGTGTACAG ATAACTACAT TAGGAATTCA TTCTTAGCTT CTTCACTCTT GTGTGGATGT

CTACCCCTTT CATTCAGGAC TGGTCCACAA GGGTGTATAC GGACAATGTC TATTGATGTA ATCCTTAAGT AAGATCGAA GAAGTAGAAA CACACCTACA

tail

hgiAI/aspHI

bsp1286

hpy188I

bsiHKAI

rmaI

ddeI

bstZ17I

bst1107I

accI

sfaNI

tsp509I

nlaIII

bbsI

bpuAI

mboII

hpy188I

maeII/hpyCH4IV

eco57I

aflIII

maeI

bspC

mboII

bmyI

btrI

bfai

mnII

1501 GTATACTTTA CGCATCTTTC CTTTGTAGTA GAGAAATTAT GTGTGTATG TGGTCTTCTG AAAATGGAAC ACCATTCTTC AGAGCACACG TCTAGCCCTC

CATATGAAAT GCGTAGAAG GAAAACTCAT CTCTTTAATA CACACAGTAC ACCAGAAGAC TTTTACCTTG TGGTAAGAAG TCTCGTGTGC AGATCGGAG

tth111I/aspl
 pleI
 pflFI
 mlyI
 hinfI
 bsmAI bsmAI
 bst4CI/hpyCH4III mnlI hpyCH4V
 1601 AGCAAGACAG TTGTTTCTCC TCCTCCTTGC ATATTTCTCA CTGCGCTCCA GCCTGAGTGA TAGAGTGAGA CTCTGTCTCA AAAAAAAGTA TCTCTAAATA
 TCGTCTCTGTC AACAAAGAGG AGGAGGAACG TATAAAGGAT GACGGGAGGT CGGACTCACT ATCTCACTCT GAGACAGAGT TTTTTCAT AGAGATTTAT

trp9I
 msel
 hpaI
 hincII/hindII
 smlI
 psiI
 1701 CAGGATTATA ATTTCTGCTT GAGTATGGTG TTAACACTCT TGTATTAGA AAGATTTCAG ATTCATTCCA TCTCCTTAGT TTTCTTTTAA GGTGACCCAT
 GTCCTAATAT TAAAGACGAA CTCATACCAC AATTGATGGA ACATAAATCT TTCTAAAGTC TAAGTAAGGT AGAGGAATCA AAAGAAAATT CCACTGGGTA

ddeI[M.aluI-]
 aluI
 1801 CTGTGATAAA AATATAGCTT AGTGCTAAA TCAGTGTAC TTATACATGG CCTAAAATGT TTCTACAAT TAGAGTTGT CACTATTCC ATTTGTACCT
 GACACTATT TTATATCGAA TCACGATTTT AGTCACATG AATATCTACC GGATTTTACA AAGATGTTTA ATCTCAACA GTGATAAGG TAAACATGGA

```

scrFI[dcM-]
pspGI
mvaI
ecORI[dcM-]
dsaV[dcM-]
bstNI
haeIII/paI
mscI/balI[dcM-]
eaeI[dcM-]
cfrI
scrFI[dcM-]
pspGI
mvaI bssKI[dcM-]
ecORI[dcM-] tsp45I
dsaV[dcM-] maeIII
bstNI hinfI
bssKI[dcM-] tspRI
pleI bslI[dcM-] hhaI/cfoI
mlyI bsaJI apyI[dcM+]
hinfI apyI[dcM+] btsI
dclI
bspCNI
1901 AAGAGAAAA TAGGCTCAGT TAGAAAAGGA CTCCTGGCC AGCGCAGTG ACTTACGCCT GTAATCTCAG CACTTTGGGA GGCCAAGGCA GGCAGATCAC
TTCTCTTTT ATCCGAGTCA ATCTTTCTCT GAGGACCGG TCCGGCTCAC TGAATGCGGA CATTAGAGTC GTGAACCCCT CCGTTCCGT CCGTCTAGTG
dclI cac8I
haeIII/paI
mnlI bsaJI
dclI
dclI
mboI/nd
dclI
dclI
bssS
hpy18
sau3AI

```

mscI/balI[dcM-]
 eaeI[dcM-]
 scrFI[dcM-]
 pspGI
 mvaI
 ecoRII[dcM-]
 dsaV[dcM-]
 bstNI

bsmAI bssKI[dcM-]

taqI foki cfrI nlaIII bsmAI

hpy188III bsaI bstFI haeIII/palI esp3I

mnlI hpy188III apyI[dcM+] hphI bsmBI

2001 GAGGTCAGGA GTTCGAGACC ATCCTGGCCA ACATGGTGAA ACCCGTCTC TACTAAAAAT ATAAAAATTA GCTGGGTGTG GTGGCAGGAG CCTGTAATCC
 CTCAGTCCT CAAGTCTGG TAGGACCGGT TGTACCACTT TGGGCGAGAG ATGATTTTAA TATTTTAAAT CGACCCACAC CACCGTCCTC GGACATTAGG

nlaIV

tsp509I

scrFI[dcM-]

pspGI

mvaI

ecoRII[dcM-]

dsaV[dcM-]

bstNI

tspRI

sau3AI

btsI

bssKI[dcM-]

apyI[dcM+]

mboI/ndeII[dam-]

hpyCH4V

dpnII[dam+] bsgI bpmI/gsuI[dcM-]

2101 CAGCTACACA GGAGGCTGAG GCACGAGAAT CACTTGAACCT CAGGAGATGG AGGTTTCAGT GAGCCGAGAT CACGCCACTG CACTCCAGCC TGGCACAAGA

GTCGATGTGT CCTCCGACTC CGTGCTCTTA GTGAACCTGA GTCCCTCTACC TCCAAAGTCA CTCGGCTCTA GTGGGTGAC GTGAGGTCGG ACCGTTGTCT

hpy188III

ddeI

tfII

bspCNI

hinFI

ddeI

mnlI mnlI bssSI

bspCNI

mnlI

tspRI

